3.0-T whole-heart coronary magnetic resonance angiography: Comparison of gadobenate dimeglumine and gadofosveset trisodium

Fabio S. Raman, Marcelo S. Nacif, George Cater, Neville Gai, Jacquin Jones, Debiao Li, Christopher Sibley, Songtao Liu, David A. Bluemke

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gadolinium enhanced coronary magnetic resonance angiography (MRA) at 3 T appears to be superior to non-contrast methods. Gadofosveset is an intravascular contrast agent that may be well suited to this application. The purpose of this study was to perform an intra-individual comparison of gadofosveset and gadobenate for coronary MRA at 3 T. In this prospective randomized study, 22 study subjects [8 (36 %) male; 27.9 ± 6 years; BMI = 22.8 ± 2 kg/m2] underwent two studies using a contrast-enhanced inversion recovery three-dimensional fast low angle shot MRA at 3 T. The order of contrast agent administration was varied randomly, separated by an average of 30 ± 5 days, using either gadobenate dimeglumine (Gd-BOPTA; Bracco, 0.1 mmol/Kg) or gadofosveset trisodium (MS-325; Lantheus Med, 0.03 mmol/Kg). Acquisition time, signal-to-noise ratio (SNR) of coronary vessels and contrast-to-noise ratio (CNR) were evaluated. Of 308 coronary arteries and veins segment analyzed, overall SNR of coronary arteries and veins segments were not different for the two contrast agents (132 ± 79 for gadofosveset vs. 135 ± 78 for gadobenate, p = 0.69). Coronary artery CNR was greater for gadofosveset in comparison to gadobenate (73.5 ± 46.9 vs. 59.3 ± 75.7 respectively, p = 0.03). Gadofosveset-enhanced MRA images displayed better image quality than gadobenate-enhanced MRA images (2.77 ± 0.61 for gadofosveset vs. 2.11 ± 0.51, p

Original languageEnglish (US)
Pages (from-to)1085-1094
Number of pages10
JournalInternational Journal of Cardiovascular Imaging
Volume29
Issue number5
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Magnetic Resonance Angiography
Coronary Angiography
Coronary Vessels
Contrast Media
Signal-To-Noise Ratio
Noise
Gadolinium
gadofosveset trisodium
gadobenic acid
Prospective Studies

Keywords

  • Coronary MRA
  • Gadobenate dimeglumine
  • Gadofosveset trisodium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

3.0-T whole-heart coronary magnetic resonance angiography : Comparison of gadobenate dimeglumine and gadofosveset trisodium. / Raman, Fabio S.; Nacif, Marcelo S.; Cater, George; Gai, Neville; Jones, Jacquin; Li, Debiao; Sibley, Christopher; Liu, Songtao; Bluemke, David A.

In: International Journal of Cardiovascular Imaging, Vol. 29, No. 5, 06.2013, p. 1085-1094.

Research output: Contribution to journalArticle

Raman, Fabio S. ; Nacif, Marcelo S. ; Cater, George ; Gai, Neville ; Jones, Jacquin ; Li, Debiao ; Sibley, Christopher ; Liu, Songtao ; Bluemke, David A. / 3.0-T whole-heart coronary magnetic resonance angiography : Comparison of gadobenate dimeglumine and gadofosveset trisodium. In: International Journal of Cardiovascular Imaging. 2013 ; Vol. 29, No. 5. pp. 1085-1094.
@article{60f2332fdce4492d88fd3efe1d4b5537,
title = "3.0-T whole-heart coronary magnetic resonance angiography: Comparison of gadobenate dimeglumine and gadofosveset trisodium",
abstract = "Gadolinium enhanced coronary magnetic resonance angiography (MRA) at 3 T appears to be superior to non-contrast methods. Gadofosveset is an intravascular contrast agent that may be well suited to this application. The purpose of this study was to perform an intra-individual comparison of gadofosveset and gadobenate for coronary MRA at 3 T. In this prospective randomized study, 22 study subjects [8 (36 {\%}) male; 27.9 ± 6 years; BMI = 22.8 ± 2 kg/m2] underwent two studies using a contrast-enhanced inversion recovery three-dimensional fast low angle shot MRA at 3 T. The order of contrast agent administration was varied randomly, separated by an average of 30 ± 5 days, using either gadobenate dimeglumine (Gd-BOPTA; Bracco, 0.1 mmol/Kg) or gadofosveset trisodium (MS-325; Lantheus Med, 0.03 mmol/Kg). Acquisition time, signal-to-noise ratio (SNR) of coronary vessels and contrast-to-noise ratio (CNR) were evaluated. Of 308 coronary arteries and veins segment analyzed, overall SNR of coronary arteries and veins segments were not different for the two contrast agents (132 ± 79 for gadofosveset vs. 135 ± 78 for gadobenate, p = 0.69). Coronary artery CNR was greater for gadofosveset in comparison to gadobenate (73.5 ± 46.9 vs. 59.3 ± 75.7 respectively, p = 0.03). Gadofosveset-enhanced MRA images displayed better image quality than gadobenate-enhanced MRA images (2.77 ± 0.61 for gadofosveset vs. 2.11 ± 0.51, p",
keywords = "Coronary MRA, Gadobenate dimeglumine, Gadofosveset trisodium",
author = "Raman, {Fabio S.} and Nacif, {Marcelo S.} and George Cater and Neville Gai and Jacquin Jones and Debiao Li and Christopher Sibley and Songtao Liu and Bluemke, {David A.}",
year = "2013",
month = "6",
doi = "10.1007/s10554-013-0192-z",
language = "English (US)",
volume = "29",
pages = "1085--1094",
journal = "International Journal of Cardiovascular Imaging",
issn = "1569-5794",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - 3.0-T whole-heart coronary magnetic resonance angiography

T2 - Comparison of gadobenate dimeglumine and gadofosveset trisodium

AU - Raman, Fabio S.

AU - Nacif, Marcelo S.

AU - Cater, George

AU - Gai, Neville

AU - Jones, Jacquin

AU - Li, Debiao

AU - Sibley, Christopher

AU - Liu, Songtao

AU - Bluemke, David A.

PY - 2013/6

Y1 - 2013/6

N2 - Gadolinium enhanced coronary magnetic resonance angiography (MRA) at 3 T appears to be superior to non-contrast methods. Gadofosveset is an intravascular contrast agent that may be well suited to this application. The purpose of this study was to perform an intra-individual comparison of gadofosveset and gadobenate for coronary MRA at 3 T. In this prospective randomized study, 22 study subjects [8 (36 %) male; 27.9 ± 6 years; BMI = 22.8 ± 2 kg/m2] underwent two studies using a contrast-enhanced inversion recovery three-dimensional fast low angle shot MRA at 3 T. The order of contrast agent administration was varied randomly, separated by an average of 30 ± 5 days, using either gadobenate dimeglumine (Gd-BOPTA; Bracco, 0.1 mmol/Kg) or gadofosveset trisodium (MS-325; Lantheus Med, 0.03 mmol/Kg). Acquisition time, signal-to-noise ratio (SNR) of coronary vessels and contrast-to-noise ratio (CNR) were evaluated. Of 308 coronary arteries and veins segment analyzed, overall SNR of coronary arteries and veins segments were not different for the two contrast agents (132 ± 79 for gadofosveset vs. 135 ± 78 for gadobenate, p = 0.69). Coronary artery CNR was greater for gadofosveset in comparison to gadobenate (73.5 ± 46.9 vs. 59.3 ± 75.7 respectively, p = 0.03). Gadofosveset-enhanced MRA images displayed better image quality than gadobenate-enhanced MRA images (2.77 ± 0.61 for gadofosveset vs. 2.11 ± 0.51, p

AB - Gadolinium enhanced coronary magnetic resonance angiography (MRA) at 3 T appears to be superior to non-contrast methods. Gadofosveset is an intravascular contrast agent that may be well suited to this application. The purpose of this study was to perform an intra-individual comparison of gadofosveset and gadobenate for coronary MRA at 3 T. In this prospective randomized study, 22 study subjects [8 (36 %) male; 27.9 ± 6 years; BMI = 22.8 ± 2 kg/m2] underwent two studies using a contrast-enhanced inversion recovery three-dimensional fast low angle shot MRA at 3 T. The order of contrast agent administration was varied randomly, separated by an average of 30 ± 5 days, using either gadobenate dimeglumine (Gd-BOPTA; Bracco, 0.1 mmol/Kg) or gadofosveset trisodium (MS-325; Lantheus Med, 0.03 mmol/Kg). Acquisition time, signal-to-noise ratio (SNR) of coronary vessels and contrast-to-noise ratio (CNR) were evaluated. Of 308 coronary arteries and veins segment analyzed, overall SNR of coronary arteries and veins segments were not different for the two contrast agents (132 ± 79 for gadofosveset vs. 135 ± 78 for gadobenate, p = 0.69). Coronary artery CNR was greater for gadofosveset in comparison to gadobenate (73.5 ± 46.9 vs. 59.3 ± 75.7 respectively, p = 0.03). Gadofosveset-enhanced MRA images displayed better image quality than gadobenate-enhanced MRA images (2.77 ± 0.61 for gadofosveset vs. 2.11 ± 0.51, p

KW - Coronary MRA

KW - Gadobenate dimeglumine

KW - Gadofosveset trisodium

UR - http://www.scopus.com/inward/record.url?scp=84893706659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893706659&partnerID=8YFLogxK

U2 - 10.1007/s10554-013-0192-z

DO - 10.1007/s10554-013-0192-z

M3 - Article

C2 - 23515949

AN - SCOPUS:84893706659

VL - 29

SP - 1085

EP - 1094

JO - International Journal of Cardiovascular Imaging

JF - International Journal of Cardiovascular Imaging

SN - 1569-5794

IS - 5

ER -